Nomura Recap of Stocks to Look Out For

Analyst M. Ian Somaiya at Nomura upgraded

from Neutral to Buy, while raising the price target from $195 to $196. "We believe rapid adoption in first-line CLL could support upside to 2015 guidance, while data from the DAWN Phase II trial in 2H15 could open a $1bn opportunity in refractory follicular lymphoma," Somaiya wrote. Analyst Jessica Schoen Mace at Nomura maintained a Buy rating on

, with a price target of $67. The key take away from the company's 2015 Investor Day was that "the company has plans in place to drive operating margin improvement over the next several years," Mace said. Analyst Robert Drbul at Nomura maintained a Buy rating on

, while raising the price target from $50 to $60. The revised price target was based on "the company's better-than-expected results in 2014, combined with our positive outlook for 2015," Drbul wrote. The EPS estimates for FY15 and FY16 were raised from $2.05 to $2.2 and from $2.4 to $2.5, respectively. Drbul at Nomura maintained a Buy rating on

, while upping the price target from $45 to $48. "Adding Stuart Vevers to the team was the most important step…and has already borne fruit as his collections continue to generate positive buzz among the fashion press both domestically and internationally," Drbul wrote. Analyst Harry C. Curtis at Nomura maintained a Buy rating on

, with a price target of $33. Curtis said he expected the company to achieve +6.5% RevPAR and system growth in 2015. The EPS estimates for FY15 and FY16 from $0.9 to $0.86 and from $1.08 to $0.99, respectively. Curtis at Nomura maintained a Buy rating on

, with a price target of $84. "We remain proponents of MAR's business model and companies like HOT that are working to replicate its corporate structure and returns," Curtis said. Curtis at Nomura maintained a Buy rating on

, with a price target of $54. "While it is gratifying to see the market respond to NCLH's well executed 4Q earnings call, the stock still offers the highest EPS growth rate in our universe at the lowest multiple," Curtis added. Analyst Brock Vandervliet at Nomura maintained a Buy rating on

, with a price target of $19.50. "We are raising our 2015 EPS estimate from $2.02 to $2.11…We reiterate our view that HTS is the best positioned agency mortgage REIT in our coverage with respect to the current environment," Vandervliet wrote. Analyst Frederick Grieb at Nomura maintained a Buy rating on

, while raising the price target from $24 to $25. The company announced 4Q14 revenues above expectations and reiterated its guidance for FY15 subscription revenue growth of 25% yoy. "While this FY'15 subscription revenue guidance is encouraging, a little more than half of this growth is due to inorganic contribution from the company's recent acquisitions of Location Labs and Norman Safeground, so slightly lower quality," Grieb said. Analyst Stuart Jeffrey at Nomura maintained a Neutral rating on

, while raising the price target from $58 to $73. "More than just Buybacks. We see MSI as a solid and stable asset that is underpinned by a share buyback that we estimate will reduce share count by 37% by 2017," Jeffrey wrote. The EPS estimate for FY15 was raised from $3.34 to $3.35. Analysts at Nomura maintained a Buy rating on

, with the price target at $74. "Efforts on boosting the perception of the Kellogg offer with the marginal consumer, notably in cereal and across the Special K brand, will be the key to success," Nomura noted. Analysts at Nomura maintained a Buy rating on

, with a price target of $56. The company "outlined an improving pricing and volume environment. It also emphasised the success in improving younger adult smoker brand preference with the development of Marlboro Black," Nomura noted. Analysts at Nomura maintained a Reduce rating on

, with a price target of $70. The company "sees less drain to profit development in Italy, Philippines and Japan in 2015. This should help offset additional spend for its HNB (heat not burn) i-QOS brand roll-out.